HUTCHMED (China) LimitedHKEX: 13

HUTCHMED to Announce 2026 Half-Year Financial Results

· Issued by HUTCHMED (China) Limited via GlobeNewswire

Summary by 6ix AI

HUTCHMED (China) Limited, a biopharmaceutical company developing cancer and immune-disease medicines, will release its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).

Key details

  • Management will host an English webcast with questions and answers for analysts and investors on Thursday, July 30, 2026 at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT.
  • A Chinese (Putonghua) webcast with questions and answers will be held at 8:30 am HKT on Friday, July 31, 2026 (1:30 am BST / 8:30 pm EDT on Thursday, July 30, 2026).
  • Both webcasts will stream live on the company website, with the presentation available to download shortly before the webcast begins and a replay posted shortly after the event.

6ix AI wrote this summary from the release below and checked it against the release.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).

HUTCHMED management will host two webcast presentations for analysts and investors to discuss the interim results, followed by Q&A sessions. The English webcast will be held on Thursday, July 30, 2026, at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT. The Chinese (Putonghua) webcast will be held at 8:30 am HKT on Friday, July 31, 2026 (1:30 am BST / 8:30 pm EDT on Thursday, July 30, 2026).

Both webcasts will be available live via the company website at www.hutch-med.com/event/. The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

Investor Enquiries

+852 2121 8200 / ir@hutch-med.com

Media Enquiries

FTI Consulting –

+44 20 3727 1030 / HUTCHMED@fticonsulting.com

Ben Atwell / Tim Stamper

+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)

Brunswick – Zhou Yi

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Panmure Liberum

Nominated Advisor and Joint Broker

Atholl Tweedie / Emma Earl / Rupert Dearden

+44 20 7886 2500

Cavendish

Joint Broker

Geoff Nash / Nigel Birks

+44 20 7220 0500

Deutsche Numis

Joint Broker

Duncan Monteith / Ramin Naji

+44 20 7545 8000

HUTCHMED (China) Limited on 6ix

Earlier from HUTCHMED (China)

Later from HUTCHMED (China)

All HUTCHMED (China) news releases